Share this on:
About this iReport
  • Not verified by CNN

  • Click to view k3vsDad's profile
    Posted January 19, 2012 by
    Farmersburg, Indiana

    More from k3vsDad

    J&J and Risperdal Take Another Hit


    Pharmaceutical  giant Johnson & Johnson continues to be hit in the pocketbook over  controversary surrounding the drug, risperdal. It is expected to be  announced today a settlement with the state of Texas that will result in  a $158 million judgement against one of its subsidiaries.

    The  company has already been hit with judgements over its marketing and  claims about risperdal in the states of Louisiana and South Carolina.  The company is planning to appeal both of those rulings that cost $258  million and $327 million respectively.

    A  lawsuit in which Texas accused Johnson & Johnson of plundering the  state Medicaid program by overstating the safety of an expensive  anti-psychotic drug and improperly influencing officials and doctors to  push the medication has been settled for $158 million, a subsidiary of  the health care giant and state officials announced Thursday.

    Texas had been seeking up to $1 billion from the drug maker.

    Janssen  Pharmaceuticals Inc., one of the J&J subsidiaries that had been  sued, said in a statement it will pay $158 million in full resolution of  all claims in Texas.

    The settlement represents a resolution to  claims brought by Texas for alleged Medicaid overpayment during the  years 1994-2008, the company said.

    From  the Cornfield, I see no justification for any pharmaceutical company to  skew the facts about its product. Put the results and findings out  there as they are.

    What do you think of this story?

    Select one of the options below. Your feedback will help tell CNN producers what to do with this iReport. If you'd like, you can explain your choice in the comments below.
    Be and editor! Choose an option below:
      Awesome! Put this on TV! Almost! Needs work. This submission violates iReport's community guidelines.


    Log in to comment

    iReport welcomes a lively discussion, so comments on iReports are not pre-screened before they post. See the iReport community guidelines for details about content that is not welcome on iReport.

    Add your Story Add your Story